Generic Name and Formulations:
Gabapentin 300mg, 600mg; tabs.
Indications for GRALISE:
Swallow whole; do not crush, split or chew tabs. Take once daily with the evening meal. ≥18yrs: initially 300mg on Day 1, 600mg on Day 2, 900mg on Days 3–6, 1200mg on Days 7–10, 1500mg on Days 11–14, titrate up to 1800mg on Day 15. Renal impairment: CrCl 30–60mL/min: 600–1800mg. CrCl <30mL/min or on hemodialysis: not recommended.
<18yrs: not recommended.
Not interchangeable with other gabapentin products. Epilepsy. Increased risk of suicidal thoughts/behavior. Monitor for worsening of depression, suicidal thoughts/behavior, and unusual changes in mood/behavior. Multiorgan hypersensitivity. Renal impairment. Avoid abrupt cessation; if discontinuing, withdraw gradually over 1 week or longer. Elderly. Pregnancy (Cat. C). Nursing mothers: not recommended.
May affect or be affected by hydrocodone. Potentiated by morphine. Separate dosing of aluminum- or magnesium-containing antacids by at least 2 hours. May cause false (+) results with urine protein tests (eg, Multistix SG).
Dizziness, somnolence, headache, lethargy, peripheral edema, diarrhea, dry mouth, pain in extremity.
Tabs 300mg—30; 600mg—90; 30-Day Starter pack—78 (9 x 300mg + 69 x 600mg)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|